Renovaro Overview
Valuation check: RENB's ROE is 1342.81%, above the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow1342.81%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Renovaro (RENB) currently reports a ROE of 1342.81%. That is above the Healthcare sector average of 21.28%. Use the charts on this page to explore Renovaro's ROE history and peer comparisons.
Renovaro's ROE of 1342.81% is higher than the Healthcare sector average of 21.28%. That is roughly 6210.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Renovaro's current 1342.81% should be judged against Healthcare norms (sector average: 21.28%) and against RENB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 1342.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Renovaro, and consider following RENB for alerts when major investors trade the stock.
Renovaro is classified in the Healthcare sector. On ROE, it currently shows 1342.81% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RENB with unrelated industries.
